Intranasal delivery of vaccines against HIV.
HIV poses a serious health threat in the world. Mucosal transmission of HIV through the genitourinary tract may be the most important route of transmission. Intranasal immunisations induce vaginal and systemic immune responses. Various protein-, DNA- and RNA-based immunopotentiating adjuvants/delivery systems and live bacterial and viral vectors are available for intranasal immunisations, and these systems may differ in their ability to induce a specific type of immune response (e.g., a cytotoxic T cell versus an antibody response). As the protection against HIV may require both cytotoxic T cell and antibodies, a combination of adjuvants/delivery systems for combinations of mucosal and parenteral immunisations may be required in order to develop a protective anti-HIV vaccine.
Vajdy
Michael
M
Chiron Vaccines, 4560 Horton Street, Emeryville, CA 94608, USA. michael_vajdy@chiron.com
Singh
Manmohan
M
D016915:AIDS Vaccines / Q000008:administration & dosage* / Q000276:immunology; D000281:Administration, Intranasal; D000818:Animals; D005822:Genetic Vectors; D006801:Humans; D018928:Immunity, Mucosal; D007114:Immunization; D012137:Respiratory System / Q000166:cytology / Q000276:immunology; D014566:Urogenital System / Q000166:cytology / Q000276:immunology
D016915:AIDS Vaccines